Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
ESMO
Filter by Topic
ESMO 2010 Conference
ESMO 2011 Conference
ESMO 2012 Conference
ESMO 2013 Conference
ESMO 2014 - Gastrointestinal and Head & Neck Cancer
ESMO 2014 - Immuno-Oncology
ESMO 2014 - Prostate Cancer
ESMO 2014 Highlights
ESMO 2016
ESMO 2017 Highlights
ESMO 2018
ESMO 2019
Record-Breaking Survival in HER2 Metastatic Breast Cancer by Adding Pertuzumab - Dual HER2 blockade a new standard of care
By
Phoebe Starr
ESMO 2014 Highlights
,
ESMO
October 2014, Vol 5 , No 8
>Madrid, Spain—Final results from the CLEOPATRA (Clinical Evaluation of Pertuzumab and Trastuzumab) trial show that dual
HER2
blockade with the combination of pertuzumab and trastuzumab plus chemotherapy extended overall survival (OS) by almost 16 months compared with trastuzumab plus chemotherapy alone in patients with
HER2
-positive metastatic breast cancer.
Read Article
Enzalutamide Long-Term Safety and Efficacy in Hormone-Naïve Prostate Cancer
ESMO 2014 - Prostate Cancer
,
ESMO
Conference Correspondent
Read Article
Maximal Androgen Depletion with Abiraterone Acetate Followed by Molecular-Targeted Therapies in Metastatic Prostate Cancer: Finding an Androgen-Signaling Signature to Predict Response
ESMO 2014 - Prostate Cancer
,
ESMO
Conference Correspondent
Read Article
Chemohormonal Therapy versus Hormonal Therapy Alone in Men with Metastatic Prostate Cancer
ESMO 2014 - Prostate Cancer
,
ESMO
Conference Correspondent
Read Article
AR-V7 Splice Variant as Prognostic Marker for Resistance to Enzalutamide or Abiraterone in Men with Metastatic Prostate Cancer
ESMO 2014 - Prostate Cancer
,
ESMO
Conference Correspondent
Read Article
Nivolumab versus Investigator’s Choice of Chemotherapy in Patients with Advanced Melanoma
ESMO 2014 - Immuno-Oncology
,
ESMO
Conference Correspondent
Read Article
Nivolumab Improves Survival in Ipilimumab-Naïve Patients with Advanced Melanoma
ESMO 2014 - Immuno-Oncology
,
ESMO
Conference Correspondent
Read Article
Two Dosing Schedules of Pembrolizumab for Patients with Advanced Melanoma
ESMO 2014 - Immuno-Oncology
,
ESMO
Conference Correspondent
Read Article
Updated OS Data for the CA184-043 Trial: Immunotherapy with Ipilimumab Does Not Improve Survival in Patients with Metastatic Prostate Cancer
ESMO 2014 - Immuno-Oncology
,
ESMO
Conference Correspondent
Read Article
Afatinib Improves Outcomes in Patients with Head and Neck Cancer
ESMO 2014 - Gastrointestinal and Head & Neck Cancer
,
ESMO
Conference Correspondent
Read Article
Page 4 of 8
1
2
3
4
5
6
7
8
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma